View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

argenx to Report First Quarter 2025 Financial Results and Business Upd...

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of th...

 PRESS RELEASE

JDE Peet’s share buyback periodic update April 28, 2025

JDE Peet’s share buyback periodic update April 28, 2025 PRESS RELEASE Amsterdam, April 28, 2025 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company, today announced that it has repurchased 34,549 shares in the period from April 21, 2025 up to and including April 25, 2025. The shares were repurchased at an average price of EUR 20.88 per share for a total consideration of EUR 0.7 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 3,556,163 ordina...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
Thomas Vranken
  • Thomas Vranken

argenx FIRST LOOK: Positive CHMP opinion for CIDP

argenx received a positive opinion from the CHMP of the EMA for Vyvgart in treating CIDP in adults with progressive or relapsing disease after prior treatment with corticosteroids or immunoglobulins. The European Commission will now decide on the regulatory submission within 60 days. Vyvgart is the first novel CIDP treatment in over 30 years and could potentially be self-administered. This approval is expected to lead to significant sales in the EU, with EU peak sales estimated at $1.1bn (KBCSe...

 PRESS RELEASE

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa)...

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a...

 PRESS RELEASE

Holding(s) in Company

easyJet plc (EZJ) Holding(s) in Company 25-Apr-2025 / 17:30 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B7KR2P84 Issuer Name EASYJET PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of financial instruments 3. Details of person subject to the notification obligation Name Bank of America Corporation City of registered office (if applicable)   Country of registered office (if applicable) US 4. Details of the shareholder Full name of shar...

 PRESS RELEASE

Board Changes

easyJet plc (EZJ) Board Changes 23-Apr-2025 / 07:00 GMT/BST 23 April 2025 easyJet plc (‘easyJet’ or the ‘Company’) Board Changes easyJet is pleased to announce that Elyes Mrad will join the Board as a Non-Executive Director and member of the Audit Committee with effect from 1 June 2025. Elyes is currently Executive Vice President, Hertz International, where he oversees the company’s business in EMEA, Latam and Asia Pacific. Before joining Hertz, he held Managing Director roles at Certares, a leading private equity firm focused on the hospitality and travel industry, and Ameri...

 PRESS RELEASE

JDE Peet’s share buyback periodic update April 22, 2025

JDE Peet’s share buyback periodic update April 22, 2025 PRESS RELEASE Amsterdam, April 22, 2025 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company, today announced that it has repurchased 40,000 shares in the period from April 14, 2025 up to and including April 17, 2025. The shares were repurchased at an average price of EUR 20.40 per share for a total consideration of EUR 0.8 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 3,521,614 ordina...

 PRESS RELEASE

JDE Peet’s share buyback periodic update April 14, 2025

JDE Peet’s share buyback periodic update April 14, 2025 PRESS RELEASE Amsterdam, April 14, 2025 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company, today announced that it has repurchased 38,272 shares in the period from April 7, 2025 up to and including April 11, 2025. The shares were repurchased at an average price of EUR 19.73 per share for a total consideration of EUR 0.8 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 3,481,614 ordinar...

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Luis de Toledo Heras
Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Luis de Toledo Heras
 PRESS RELEASE

argenx Announces Annual General Meeting of Shareholders on May 27, 202...

argenx Announces Annual General Meeting of Shareholders on May 27, 2025 April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meet...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch